Low concentrations of medium-sized HDL particles predict incident CVD in chronic kidney disease patients

[1]  S. Pennathur,et al.  Altered HDL proteome predicts incident CVD in chronic kidney disease patients , 2021, Journal of lipid research.

[2]  M. Järvelin,et al.  Apt interpretation of comprehensive lipoprotein data in large-scale epidemiology: disclosure of fundamental structural and metabolic relationships , 2021, medRxiv.

[3]  G. Jarvik,et al.  Diabetes Impairs Cellular Cholesterol Efflux From ABCA1 to Small HDL Particles , 2020, Circulation research.

[4]  G. Michailidis,et al.  Plasma lipidomic profiling identifies a novel complex lipid signature associated with ischemic stroke in chronic kidney disease , 2020, Journal of translational science.

[5]  S. Pennathur,et al.  Lipids and Cardiovascular Risk with CKD. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[6]  Hetal S. Shah,et al.  High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes , 2019, Diabetes Care.

[7]  P. Joshi,et al.  Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events. , 2018, Journal of the American College of Cardiology.

[8]  S. Nicholls.  CETP‐Inhibition and HDL‐Cholesterol: A Story of CV Risk or CV Benefit, or Both , 2018, Clinical pharmacology and therapeutics.

[9]  E. Schaefer,et al.  HDL Particle Measurement: Comparison of 5 Methods. , 2018, Clinical chemistry.

[10]  Subramaniam Pennathur,et al.  Impaired β-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD. , 2017, Journal of the American Society of Nephrology : JASN.

[11]  Michael Holzer,et al.  HDL structure and function is profoundly affected when stored frozen in the absence of cryoprotectants[S] , 2017, Journal of Lipid Research.

[12]  Olga V. Demler,et al.  Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) , 2017, Circulation.

[13]  C. Wanner,et al.  HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients. , 2017, Journal of the American Society of Nephrology : JASN.

[14]  D. Fliser,et al.  HDL Cholesterol Efflux Capacity and Cardiovascular Events in Patients With Chronic Kidney Disease. , 2017, Journal of the American College of Cardiology.

[15]  Jiang He,et al.  Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort , 2016, Kidney international reports.

[16]  A. Lerman,et al.  Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration. , 2016, Circulation research.

[17]  Michael J. Thomas,et al.  Microdomains, Inflammation, and Atherosclerosis. , 2016, Circulation research.

[18]  A. Kontush.  HDL particle number and size as predictors of cardiovascular disease , 2015, Front. Pharmacol..

[19]  D. Rader,et al.  Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study , 2015, The lancet. Diabetes & endocrinology.

[20]  K. Rye,et al.  HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. , 2015, Circulation research.

[21]  A. Khera,et al.  HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.

[22]  G. Jarvik,et al.  Quantification of HDL particle concentration by calibrated ion mobility analysis. , 2014, Clinical chemistry.

[23]  K. Kalantar-Zadeh,et al.  Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  A. Sharrett,et al.  Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study. , 2014, Atherosclerosis.

[25]  N. Brot,et al.  Humans With Atherosclerosis Have Impaired ABCA1 Cholesterol Efflux and Enhanced High-Density Lipoprotein Oxidation by Myeloperoxidase , 2014, Circulation research.

[26]  P. Ridker,et al.  High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy , 2013, Circulation.

[27]  T. Ikizler,et al.  Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. , 2012, Journal of the American College of Cardiology.

[28]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[29]  Samia Mora,et al.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). , 2012, Journal of the American College of Cardiology.

[30]  R. Collins,et al.  Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study , 2012, Circulation.

[31]  R. Birner-Gruenberger,et al.  Uremia alters HDL composition and function. , 2011, Journal of the American Society of Nephrology : JASN.

[32]  R. Krauss,et al.  HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. , 2011, Clinical chemistry.

[33]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[34]  G. Francis.  The complexity of HDL. , 2010, Biochimica et biophysica acta.

[35]  D. Rader,et al.  The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[36]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[37]  Paul T. Williams,et al.  Ion Mobility Analysis of Lipoprotein Subfractions Identifies Three Independent Axes of Cardiovascular Risk , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[38]  A. Kontush,et al.  Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[39]  N. Wareham,et al.  High-Density Lipoprotein Particle Size and Concentration and Coronary Risk , 2009, Annals of Internal Medicine.

[40]  A. Tall,et al.  Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins , 2008, Journal of internal medicine.

[41]  Christina Lindahl,et al.  High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. , 2008, Journal of the American College of Cardiology.

[42]  L. Kuller,et al.  Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. , 2007, Atherosclerosis.

[43]  M. Couturier,et al.  Preferential Sphingosine-1-Phosphate Enrichment and Sphingomyelin Depletion Are Key Features of Small Dense HDL3 Particles: Relevance to Antiapoptotic and Antioxidative Activities , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[44]  H. Bloomfield,et al.  Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.

[45]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[46]  A. Tward,et al.  Decreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic Mice , 2002, Circulation.

[47]  Alice Arnold,et al.  Nuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[48]  G. Schellenberg,et al.  Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[49]  I. Myara,et al.  The effect of high density lipoprotein subfractions on endothelial eicosanoid secretion. , 1998, Thrombosis research.

[50]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[51]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.

[52]  J. Otvos,et al.  Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. , 2002, Clinical laboratory.

[53]  G. Schellenberg,et al.  Paraoxonase ( PON 1 ) Phenotype Is a Better Predictor of Vascular Disease Than Is PON 1 192 or PON 1 55 Genotype , 2000 .